Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other

Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand

By The Northwire Desk — AI Analysis Feb 11, 2026 · 07:00 ACB · 4.86 AURORA CANNABIS INC. J
ACB · Price

Executive Summary

  • Aurora Cannabis announced the launch of six new medical‑cannabis products in Australia and New Zealand, expanding its international medical portfolio.
  • The rollout includes two THC flower varieties in New Zealand (Big Wave™ and Night Ride™) with a third hybrid strain (Half Moon™) slated for Q1 FY27, plus four resin cartridge SKUs in Australia.
  • The new products are manufactured at Aurora’s EU‑GMP and TGA‑GMP certified facilities in Canada, underscoring the company’s commitment to quality and growth in its largest overseas medical markets.

Key Details

  • New Zealand – Flower Launches
  • Big Wave™ – Hybrid flower, THC 26%, CBD <1%
  • Night Ride™ – Indica flower, THC 29%, CBD <1%

  • Half Moon™ – Hybrid flower (launch Q1 FY27), THC 9%, CBD 13%

  • Australia – Resin Cartridge Launches (all 780 mg/g THC, <10 mg/g CBD)

  • Chemango™ Kush – Indica cartridge
  • Cosmic Cream™ – Indica cartridge
  • Lunar Express™ – Indica cartridge

  • Soul Train Haze™ – Sativa cartridge

  • Products are derived from Aurora’s proprietary genetics and produced at EU‑GMP (Germany) and TGA‑GMP (Canada) certified facilities.

  • Statement from Stanley Sack, Interim Managing Director of MedReleaf Australia, emphasizing Australia as a top priority market and the company’s commitment to diversified, high‑quality medical formats.

  • The expansion aligns with Aurora’s long‑term global growth strategy and its focus on high‑margin opportunities in key international markets.

Notable Quotes

“With Australia being one of our largest international medical cannabis market, both Australia and New Zealand remain a top priority for Aurora, and we are deeply committed to our continued investment across the region,” – Stanley Sack, Interim Managing Director, MedReleaf Australia.

Read the original news release →

More from AURORA CANNABIS INC. J

Jun 11, 2026 · 07:05

Record FY2026 revenue masks structural margin contraction and explicit FY2027 guide-cut; cash-rich but capital allocation remains dilutive.

Earnings May 14, 2026 · 08:45

Aurora Cannabis Secures IP Rights Amidst Sector Consolidation and Price Stabilization

M&A / Property May 14, 2026 · 06:54

Aurora Secures IP Moat Amidst Dilution Concerns and Cash Burn

M&A / Property Apr 28, 2026 · 15:57

Aurora Cannabis Expands Global Medical Portfolio Amidst Dilution Concerns and Profitability Push

Production / Operations Apr 28, 2026 · 06:53

Product Expansion Validates EU Capacity Play, But Dilution Risk Looms Over Cash Burn

Production / Operations Apr 15, 2026 · 07:05

Aurora Cannabis Acquires EU GMP Capacity Amidst Stock Decline

M&A / Property